SCHEMBL6772165

SCHEMBL6772165

Fc1ccc(-c2nnn(CCOCc3ccccc3)c2-c2ccncc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.58
MAPK13 O15264 6/20 0.47
MAPK12 P53778 6/20 0.47
MAPK11 Q15759 5/20 0.47
CDC7 O00311 2/20 0.43
DAPK3 O43293 2/20 0.43
ROCK2 O75116 2/20 0.43
PRKD3 O94806 2/20 0.43
MAP4K4 O95819 2/20 0.43
PRKACA P17612 2/20 0.43
CDK2 P24941 2/20 0.43
FLT3 P36888 2/20 0.43
CLK2 P49760 2/20 0.43
GSK3B P49841 2/20 0.43
CDK9 P50750 2/20 0.43
PRKX P51817 2/20 0.43
JAK3 P52333 2/20 0.43
CDK5 Q00535 2/20 0.43
MAP4K2 Q12851 2/20 0.43
CAMK2D Q13557 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773691 0.89 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11CDC7
SCHEMBL6773026 0.84 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11MAPK10
SCHEMBL6769729 0.84 MAPK14 (0.78) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6773358 0.82 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6768638 0.81 MAPK14 (0.66) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6772940 0.80 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11MAPK10
SCHEMBL6779785 0.79 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11MAPK10
SCHEMBL6029394 0.77 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11SLC34A1
SCHEMBL6772887 0.75 MAPK14 (0.76) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6028660 0.75 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US claimed
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity PROCTER & GAMBLE COMPANY, THE 2003-01-16 US claimed
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity IL4, IL1A, IL2 MAPK14 3429/4885MAPK13 4097/4885MAPK12 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.